Show simple item record

dc.contributor.authorLangeveld, Mirjamen
dc.contributor.authorTan, Chong Yewen
dc.contributor.authorSoeters, Maarten Ren
dc.contributor.authorVirtue, Samuelen
dc.contributor.authorWatson, Laura Peen
dc.contributor.authorMurgatroyd, Peter Ren
dc.contributor.authorAmbler, Graeme Ken
dc.contributor.authorVidal-Puig, Santiagoen
dc.contributor.authorChatterjee, Krishnaen
dc.contributor.authorVidal-Puig, Antonioen
dc.date.accessioned2018-04-11T14:46:48Z
dc.date.available2018-04-11T14:46:48Z
dc.date.issued2017-11en
dc.identifier.issn0002-9165
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/274787
dc.description.abstractABSTRACT Background: Induction of nonshivering thermogenesis can be used to influence energy balance to prevent or even treat obesity. The pungent component of mustard, allyl-isothiocyanate (AITC), activates the extreme ½AQ3 cold receptor transient receptor potential channel, subfamily A, member 1 and may thus induce energy expenditure and metabolic changes. Objective: The objective of our study was to evaluate the potential of mustard AITC to induce thermogenesis (primary outcome) and alter body temperature, cold and hunger sensations, plasma metabolic parameters, and energy intake (secondary outcomes). Design: Energy expenditure in mice was measured after subcutane½ AQ4 ous injection with vehicle, 1 mg norepinephrine/kg, ½AQ5 or 5 mg AITC/kg. In our human crossover study, 11 healthy subjects were studied under temperature-controlled conditions after an overnight fast. After ingestion of 10 g of capsulated mustard or uncapsulated ½AQ6 mustard or a capsulated placebo mixture, measurements of energy expenditure, substrate oxidation, core temperature, cold and hunger scores, and plasma parameters were repeated every 30 min during a 150-min period. Subjects were randomly selected for the placebo and capsulated mustard intervention; 9 of 11 subjects received the uncapsulated mustard as the final intervention because this could not be blinded. After the experiments, energy intake was measured with the universal eating monitor in a test meal. Results: In mice, AITC administration induced a 32% increase in energy expenditure compared with placebo (17.5 6 4.9 J $ min21 $ mouse21 compared with 12.5 6 1.2 J $ min21 $ mouse21, P = 0.03). Of the 11 randomly selected participants, 1 was excluded because of intercurrent illness after the first visit and 1 withdrew after the second visit. Energy expenditure did not increase after ingestion of capsulated or uncapsulated mustard compared with placebo. No differences in substrate oxidation, core temperature, cold and hunger scores, or plasma parameters were found, nor was the energy intake at the end of the experiment different between the 3 conditions. Conclusion: The highest tolerable dose of mustard we were able to use did not elicit a relevant thermogenic response in humans. This trial was registered at www.controlled-trials.com as ISRCTN19147515. Am J Clin Nutr 2017;106:1–9.
dc.format.mediumPrint-Electronicen
dc.languageengen
dc.publisherAmerican Society for Clinical Nutrition, Inc.
dc.rightsAttribution 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectAnimalsen
dc.subjectHumansen
dc.subjectMiceen
dc.subjectMustard Planten
dc.subjectNorepinephrineen
dc.subjectIsothiocyanatesen
dc.subjectBlood Glucoseen
dc.subjectBody Temperatureen
dc.subjectCross-Over Studiesen
dc.subjectHungeren
dc.subjectEnergy Metabolismen
dc.subjectOxygen Consumptionen
dc.subjectEnergy Intakeen
dc.subjectThermogenesisen
dc.subjectAdolescenten
dc.subjectAdulten
dc.subjectAgeden
dc.subjectMiddle Ageden
dc.subjectFemaleen
dc.subjectMaleen
dc.subjectYoung Adulten
dc.titleNo metabolic effects of mustard allyl-isothiocyanate compared with placebo in men.en
dc.typeArticle
prism.endingPage1205
prism.issueIdentifier5en
prism.publicationDate2017en
prism.publicationNameThe American journal of clinical nutritionen
prism.startingPage1197
prism.volume106en
dc.identifier.doi10.17863/CAM.13827
dcterms.dateAccepted2017-09-11en
rioxxterms.versionofrecord10.3945/ajcn.116.148395en
rioxxterms.versionVoR*
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserveden
rioxxterms.licenseref.startdate2017-11en
dc.contributor.orcidLangeveld, Mirjam [0000-0002-9934-6831]
dc.contributor.orcidAmbler, Graeme K [0000-0002-3024-6365]
dc.contributor.orcidChatterjee, Krishna [0000-0002-2654-8854]
dc.contributor.orcidVidal-Puig, Antonio [0000-0003-4220-9577]
dc.identifier.eissn1938-3207
rioxxterms.typeJournal Article/Reviewen
pubs.funder-project-idWellcome Trust (095564/Z/11/Z)
pubs.funder-project-idBBSRC (BB/J009865/1)
pubs.funder-project-idMRC (MC_UU_12012/2)
pubs.funder-project-idMRC (MC_UU_12012/5)
pubs.funder-project-idBritish Heart Foundation (PG/12/53/29714)
pubs.funder-project-idDepartment of Health (via National Institute for Health Research (NIHR)) (NF-SI-0514-10176)
cam.orpheus.successThu Jan 30 12:58:26 GMT 2020 - The item has an open VoR version.*
rioxxterms.freetoread.startdate2100-01-01


Files in this item

Thumbnail
Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution 4.0 International
Except where otherwise noted, this item's licence is described as Attribution 4.0 International